Last reviewed · How we verify
T89 capsule
T89 is a traditional Chinese medicine-derived compound that improves myocardial energy metabolism and enhances cardiac function through multiple pathways.
T89 is a traditional Chinese medicine-derived compound that improves myocardial energy metabolism and enhances cardiac function through multiple pathways. Used for Angina pectoris, Myocardial infarction, Heart failure.
At a glance
| Generic name | T89 capsule |
|---|---|
| Also known as | Dantonic, Dantonic Capsule, Cardiotonic Pills |
| Sponsor | Tasly Pharmaceuticals, Inc. |
| Drug class | Herbal/Traditional medicine derivative; cardiac metabolic agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
T89 (Danshen dripping pill active components) works by improving coronary blood flow, reducing myocardial oxygen consumption, and enhancing ATP production in cardiac mitochondria. It acts through multiple mechanisms including anti-inflammatory effects, antioxidant activity, and modulation of calcium handling in cardiomyocytes, thereby improving overall cardiac contractility and reducing ischemic injury.
Approved indications
- Angina pectoris
- Myocardial infarction
- Heart failure
Common side effects
- Gastrointestinal disturbance
- Dizziness
- Headache
Key clinical trials
- Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina (PHASE3)
- Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) (PHASE3)
- Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19
- Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) (PHASE2)
- Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina (PHASE3)
- Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina (PHASE2)
- A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T89 capsule CI brief — competitive landscape report
- T89 capsule updates RSS · CI watch RSS
- Tasly Pharmaceuticals, Inc. portfolio CI